First ever HIV immunotherapy, involving ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals, proves safe in human phase 1 clinical trial, as reported in the journal Molecular Therapy.

See the source article by following the link below:
First ever HIV immunotherapy, involving ex vivo expansion of T cells and their subsequent infusion into HIV-infected individuals, proves safe in human phase 1 clinical trial, as reported in the journal Molecular Therapy.